Boston Scientific (BSX) Asset Writedowns and Impairment (2010 - 2025)

Boston Scientific has disclosed Asset Writedowns and Impairment across 7 years of filings, most recently posting -$27.0 million for Q4 2025.

• Asset Writedowns and Impairment for Q4 2025 came in at -$27.0 million, down 164.29% year-over-year; the trailing twelve-month figure through Dec 2025 was -$204.0 million (up 12.82% YoY), and the FY2025 annual result was $46.0 million, down 36.11% from the prior year.
• Asset Writedowns and Impairment came in at -$27.0 million for Q4 2025 at Boston Scientific, down from $27.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $197.0 million in Q4 2021 to a low of -$246.0 million in Q3 2024.
• The 5-year median for Asset Writedowns and Impairment is $34.5 million (2024), against an average of $26.1 million.
• Peak annual rise in Asset Writedowns and Impairment reached 235.48% in 2024, while the deepest fall reached 24700.0% in 2024.
• Boston Scientific's Asset Writedowns and Impairment stood at $197.0 million in 2021, then tumbled by 36.55% to $125.0 million in 2022, then sank by 124.8% to -$31.0 million in 2023, then jumped by 235.48% to $42.0 million in 2024, then plunged by 164.29% to -$27.0 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at -$27.0 million (Q4 2025), $27.0 million (Q3 2025), and $42.0 million (Q4 2024), per Business Quant data.